Simcere has been continuously expanding its R&D investments. In 2022, its R&D investment was more than CNY 1.7 billion, accounting for 27.3% of the sales revenue.
With five R&D centers in Shanghai, Nanjing, Beijing, Boston and HongKong, the company has established a whole-process R&D system integrating drug discovery, pre-clinical development, clinical trials, and drug registration.
Additionally, the company has established an R&D team comprising over 1000 professionals, of whom more than 60% are professionals with a master's or doctoral degree and more than 10% are professionals with an international education background.